Company news
Kura Oncology, Inc. news in 2026
Kura Oncology, Inc.'s news releases, calls and decks from 2026, newest first.
Kura Oncology to Participate in Two Investor Conferences in November
November 13, 2026
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
November 10, 2026
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 6, 2026
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
November 4, 2026
Kura Oncology to Report Third Quarter Financial Results on November 10
November 3, 2026
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
October 13, 2026
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
October 7, 2026
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
A Taste of Mystery: Kura Sushi USA and Crunchyroll Brew Up a New Collab with The Apothecary Diaries
September 17, 2026
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
September 9, 2026
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
September 8, 2026
Kura Oncology to Participate in Three Investor Conferences in September
September 1, 2026
Kura Oncology Reports Second Quarter 2026 Financial Results
August 12, 2026
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity
August 11, 2026
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
August 10, 2026
Kura Oncology to Report Second Quarter Financial Results
August 5, 2026
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
July 27, 2026
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
July 14, 2026
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
June 11, 2026
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
June 8, 2026
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
June 3, 2026
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
June 1, 2026
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
May 26, 2026
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
May 18, 2026
Kura Oncology Reports First Quarter 2026 Financial Results
May 12, 2026
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026
Kura Oncology to Report First Quarter 2026 Financial Results
May 5, 2026
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
April 24, 2026
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
April 17, 2026
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
April 9, 2026
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2026
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
January 10, 2026
Calls in 2026
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 48 slides · Aug 12, 2026
- Technical Presentation (July 2026)
Technical · 10 slides · July 2026
- Q4 2025 Earnings Presentation
Earnings · 32 slides · Mar 5, 2026
- Technical Presentation (2026)
Technical · 18 slides · 2026